Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background and Purpose Following the positive results from recent trials on endovascular therapy (EVT), bridging therapy (intravenous alteplase plus EVT) is increasingly being used for the treatment of acute ischemic stroke. However, the optimal dose of intravenous alteplase remains unknown in centers where bridging therapy is actively performed. The optimal dose for eventual recanalization and positive clinical outcomes in patients receiving bridging therapy also remains unknown. Methods In this prospective Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) sub-study, we explored the outcomes following treatment with two different doses (low- [0.6 mg/kg] or standard-dose [0.9 mg/kg]) of intravenous alteplase across 12 Korean centers where EVT is actively performed. The primary endpoint was a favorable outcome at 90 days (modified Rankin Scale scores 0 to 1). Secondary endpoints included symptomatic intracerebral hemorrhage (ICH) in all patients, and the recanalization rate and favorable outcome in patients who underwent cerebral angiography for EVT (ClinicalTrials.gov, number NCT01422616). Results Of 351 patients, the primary outcome occurred in 46% of patients in both the standard- (80/173) and low-dose (81/178) groups (odds ratio [OR], 1.14; 95% confidence interval [CI], 0.72 to 1.81; P=0.582), although ICHs tended to occur more frequently in the standard-dose group (8% vs.3%, P=0.056). Of the 67 patients who underwent cerebral angiography, there was no significant difference in favorable functional outcome between the standard- and low-dose groups (39% vs.21%; OR, 2.39; 95% CI, 0.73 to 7.78; P=0.149). Conclusions There was no difference in functional outcome between the patients receiving different doses of alteplase in centers actively performing bridging therapy.
Abstract
Background and Purpose Following the positive results from recent trials on endovascular therapy (EVT), bridging therapy (intravenous alteplase plus EVT) is increasingly being used for the treatment of acute ischemic stroke. However, the optimal dose of intravenous alteplase remains unknown in centers where bridging therapy is actively performed. The optimal dose for eventual recanalization and positive clinical outcomes in patients receiving bridging therapy also remains unknown. Methods In this prospective Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) sub-study, we explored the outcomes following treatment with two different doses (low- [0.6 mg/kg] or standard-dose [0.9 mg/kg]) of intravenous alteplase across 12 Korean centers where EVT is actively performed. The primary endpoint was a favorable outcome at 90 days (modified Rankin Scale scores 0 to 1). Secondary endpoints included symptomatic intracerebral hemorrhage (ICH) in all patients, and the recanalization rate and favorable outcome in patients who underwent cerebral angiography for EVT (ClinicalTrials.gov, number NCT01422616). Results Of 351 patients, the primary outcome occurred in 46% of patients in both the standard- (80/173) and low-dose (81/178) groups (odds ratio [OR], 1.14; 95% confidence interval [CI], 0.72 to 1.81; P=0.582), although ICHs tended to occur more frequently in the standard-dose group (8% vs.3%, P=0.056). Of the 67 patients who underwent cerebral angiography, there was no significant difference in favorable functional outcome between the standard- and low-dose groups (39% vs.21%; OR, 2.39; 95% CI, 0.73 to 7.78; P=0.149). Conclusions There was no difference in functional outcome between the patients receiving different doses of alteplase in centers actively performing bridging therapy.
참고문헌 (18)
- Anderson CS, "Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke", N Engl J Med, 374, pp.2313~2323 (2016)[DOI]
- Berkhemer OA, "A randomized trial of intraarterial treatment for acute ischemic stroke", N Engl J Med, 372, pp.11~20 (2015)[DOI]
- Jovin TG, "Thrombectomy within 8 hours after symptom onset in ischemic stroke", N Engl J Med, 372, pp.2296~2306 (2015)[DOI]
- Goyal M, "Randomized assessment of rapid endovascular treatment of ischemic stroke", N Engl J Med, 372, pp.1019~1030 (2015)[DOI]
- Campbell BC, "Endovascular therapy for ischemic stroke with perfusion- imaging selection", N Engl J Med, 372, pp.1009~1018 (2015)[DOI]
- Saver JL, "Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke", N Eng J Med, 372, pp.2285~2295 (2015)[DOI]
- 홍근식, "Endovascular Recanalization Therapy in Acute Ischemic Stroke: Updated Meta-analysis of Randomized Controlled Trials", 대한뇌졸중영문학회지, 17(3), pp.268~281 (2015), 대한뇌졸중학회
- Huang Y, "Rationale, design, and progress of the enhanced control of hypertension and thrombolysis stroke study (ENCHANTED) trial: an international multicenter 2 <TEX>$\times$<", TEX> 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment, 2015, pp.10, 778~788
- Anderson CS, "Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the enhanced control of hypertension and thrombolysis stroke study (ENCHANTED)", Int J Stroke, 10, pp.1313~1315 (2015)
- Quinn TJ, "Functional outcome measures in contemporary stroke trials", Int J Stroke, 4, pp.200~205 (2009)[DOI]
- Lyden P, "Improved reliability of the NIH stroke scale using video training. NINDS TPA Stroke Study Group", Stroke, 25, pp.2220~2226 (1994)[DOI]
- National Institute of Neurological Disorders, "Tissue plasminogen activator for acute ischemic stroke", N Eng J Med, 333, pp.1581~1587 (1995)[DOI]
- Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)[DOI]
- Wahlgren N, "Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study", Lancet, 369, pp.275~282 (2007)[DOI]
- Tomsick T, "Revascularization results in the interventional Management Of Stroke II Trial", AJNR AJNR Am J Neuroradiol, 29, pp.582~587 (2008)[DOI]
- Saqqur M, "Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke", Stroke, 38, pp.948~954 (2007)[DOI]
- Georgiadis AL, "Comparison of partial (.6 mg", kg) versus full-dose (.9 mg, J Neuroimaging, pp.2011, 21[DOI]
- Keun-Sik Hong, "Update of the Korean Clinical Practice Guidelines for Endovascular Recanalization Therapy in Patients with Acute Ischemic Stroke", 대한뇌졸중영문학회지, 18(1), pp.102~113 (2016), 대한뇌졸중학회